Once dismissed as “junk,” a group of RNA molecules has been found to help regrow damaged nerves in mice in new research. The ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

Visitors to the Watson-Marlow Fluid Technology Solutions booth W15-2 at INTERPHEX Tokyo 2025 (July 9-11 at Tokyo Big Sight, Japan) can learn more about the new WMArchitect Interchangeable Parts ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies.

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.